Clinical trials: Patients with Advanced Solid Tumors
Lung Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Bortezomib and Pemetrexed Disodium in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors
RATIONALE: Bortezomib and pemetrexed disodium may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving bortezomib together with pemetrexed disodium may kill more tumor cells.
- Trial name
- NCT00389805
- Testing
- bortezomib, pemetrexed disodium, gene expression analysis
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- University of California, Davis
Epithelial Ovarian Cancer, Peritoneal Cancer
Study of Avelumab With or Without Entinostat in Participants With Advanced Epithelial Ovarian Cancer
The purpose of this study is to determine the biologically active dose of entinostat, when given in combination with avelumab, that is safe and warrants further investigation.
- Conditions
- Epithelial Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
- Trial name
- NCT02915523
- Testing
- entinostat, avelumab
- Where
- 12 sites in United States
- Volunteers
- 140 people
- Sponsor
- Syndax Pharmaceuticals
Solid Tumor, TNBC - Triple-Negative Breast Cancer
TH1902 in Patients With Advanced Solid Tumors
Open label first-in-human study of TH1902 in solid cancer, with 4 sequential parts: Part 1 (dose escalation): patients with recurrent advanced solid tumors (all comers) that have relapsed or are refractory to standard…
- Conditions
- Solid Tumor, TNBC - Triple-Negative Breast Cancer, Hormone Receptor-positive Breast Cancer, Epithelial Ovarian Cancer
- Trial name
- NCT04706962
- Testing
- TH1902
- Where
- 6 sites in United States, Canada
- Volunteers
- 70 people
- Sponsor
- Theratechnologies
Advanced Solid Tumors
Study of Oral Darinaparsin in Patients With Advanced Solid Tumors
This study is a Phase I, dose escalation study of oral darinaparsin for the treatment of advanced solid tumors. Eligible patients could have received any amount of previous therapy.
- Trial name
- NCT01139346
- Testing
- darinaparsin
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- Alaunos Therapeutics
Advanced Cancer, Metastatic Cancer
A Open Label Phase I/II Clinical Trial to Evaluate CPI-613 in Patients With Advanced Malignancies
An open label, dose-escalation study to evaluate safety, tolerability, maximum tolerated dose (MTD), efficacy, and pharmacokinetics (PKs) of CPI-613 given twice weekly for three consecutive weeks in cancer patients The objectives…
- Conditions
- Advanced Cancer, Metastatic Cancer, Lymphoma, Solid Tumors
- Trial name
- NCT00741403
- Testing
- CPI-613
- Where
- 4 sites in United States, Canada
- Volunteers
- 39 people
- Sponsor
- Cornerstone Pharmaceuticals
Advanced or Metastatic Solid Tumors, Cancer
A Dose Escalation Study of SF1126, a PI3 Kinase (PI3K) Inhibitor, Given By Intravenous (IV) Infusion in Patients With Solid Tumors
The purpose of this study is to evaluate the safety and tolerability of SF1126 in patients with advanced or metastatic tumors by assessing the dose limiting toxicities (DLTs) and defining the maximum tolerated dose given twice…
- Conditions
- Advanced or Metastatic Solid Tumors, Cancer, Solid Cancers
- Trial name
- SF112600106 (NCT00907205)
- Testing
- SF1126
- Where
- 4 sites in United States
- Volunteers
- 44 people
- Sponsor
- Semafore Pharmaceuticals
Solid Tumor, Lymphoma, Non-Hodgkin
A Phase Ia Clinical Study of QLF31907 Injection in Patients With Advanced Malignant Tumors
This study is designed to evaluate the safety and tolerability of QLF31907 injection, to identify the maximum tolerated dose (MTD) and dose-limiting toxicity(DLT), and determine the recommended phase Ib dose(RPIbD) and…
- Trial name
- NCT05150405
- Testing
- QLF31907
- Where
- China
- Volunteers
- 54 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Advanced Cancer
Trial of Olaparib in Combination With AZD5363 (ComPAKT)
This is a phase I trial of the combination of the PARP inhibitor olaparib and AKT inhibitor AZD5363. There are two parts to this study. Part A: dose escalation, and Part B: dose expansion.
- Trial name
- ComPAKT (NCT02338622)
- Testing
- olaparib, AZD5363
- Where
- 2 sites in United Kingdom
- Volunteers
- 60 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Pancreatic Adenocarcinoma, Esophageal Adenocarcinoma
GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma
This first-in-human (FIH ) study is an open-label, multicenter study that consists of a Phase 1 Dose Escalation/Expansion phase of GB1275 monotherapy or in combination with Anti-PD-1 Antibody or in combination with Standard of…
- Conditions
- Pancreatic Adenocarcinoma, Esophageal Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma
- Trial name
- NCT04060342
- Testing
- GB1275, nab-paclitaxel and gemcitabine, pembrolizumab
- Where
- 8 sites in United States, United Kingdom
- Volunteers
- 61 people
- Sponsor
- GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.
Locally Advanced or Metastatic Solid Tumors
Clinical Study of SM3321 With Solid Tumors
The purpose of this study is to evaluate the Safety and Tolerability of SM3321 in patients with locally advanced or metastatic solid tumors
- Trial name
- NCT06087770
- Testing
- SM3321
- Where
- 3 sites in China
- Volunteers
- 7 people
- Sponsor
- Beijing StarMab Biomed Technology Ltd
Advanced or Metastatic Solid Tumors
Phase I of XKH002 Injection in Patients
This is a Phase 1, first-in-human (FIH), open-label, multicenter, dose-escalation and dose-expansion study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of XKH002 in patients with advanced or…
- Trial name
- NCT06196762
- Testing
- XKH002 Injection
- Where
- China
- Volunteers
- 110 people
- Sponsor
- Zhejiang Kanova Biopharmaceutical Co., LTD
Tumor, Solid, Cancer, Metastatic
Phase I Study of SHR9146 + SHR-1210 +/- Apatinib in Patients With Advanced Solid Tumors
This phase I trial is designed to efficiently identify the dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) for the combination therapy regimen of the IDO1 inhibitor SHR9146 when administered in combination with…
- Conditions
- Tumor, Solid, Cancer, Metastatic, Neoplasm Malignant
- Trial name
- NCT03491631
- Testing
- SHR9146+SHR-1210, SHR9146+SHR-1210+Apatinib
- Where
- China
- Volunteers
- 23 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Cancer
Weekly Topotecan in Combination With Carboplatin in Two Different Schedules for Refractory and/or Advanced Solid Tumors
In this phase I study we will characterize the safety, tolerability, maximum tolerated dose and dose-limiting toxicity of weekly bolus topotecan when administered in combination with two different dosing schedules of carboplatin.
- Trial name
- NCT00193583
- Testing
- Topotecan, Carboplatin
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- SCRI Development Innovations, LLC
Cancer, Tumors
Detection of Tumor DNA in Blood Samples From Cancer Patients
The aim of this study is to employ genomic detection methodologies to measure the relative amount of tumor nucleic acids in the blood of a cancer patient with diagnosed metastatic disease that is either commencing, currently…
- Trial name
- NCT02288754
- Testing
- Blood test
- Where
- United States
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Lexent Bio, Inc.
Solid Tumor
Safety and Efficacy of an Autologous Tumor Infiltrating Lymphocyte (TIL) Therapy in Patients with Advanced Solid Tumors
Multicenter, single arm, non-randomized, prospective, open label, interventional study evaluating adoptive cell therapy (ACT) with autologous tumor infiltrating lymphocytes (TIL) infusion (BEN101) followed by IL-2 after a…
- Trial name
- NCT05831033
- Testing
- BEN101
- Where
- 3 sites in China
- Volunteers
- 16 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Advanced Solid Neoplasm
A Study to Evaluate the Effects of Rifampin on Pharmacokinetics (PK) of Pevonedistat in Participants With Advanced Solid Tumors
The purpose of this study is to assess the effect of multiple-dose administration of rifampin on the single dose PK of pevonedistat in adult participants with advanced solid tumors.
- Trial name
- NCT03486314
- Testing
- Pevonedistat, Rifampin, Docetaxel
- Where
- 4 sites in United States
- Volunteers
- 20 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Solid Tumor Cancer, Lymphoma
Dose-Escalating Study Of SB-485232 Administered Intravenously Every 28 Days To Adults With Solid Tumors Or Lymphomas
SB-485232 will be administered as five daily intravenous (IV) infusions repeated every 28 days in adult subjects with advanced solid tumors or lymphomas.
- Trial name
- NCT00085904
- Testing
- SB-485232
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- GlaxoSmithKline
Advanced Solid Tumors
Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of BAT8008 for Injection
Objectives:To evaluate the safety and tolerability of BAT8008 for injection in patients with advanced solid tumors, explore the maximum tolerated dose (MTD), and provide the recommended dose for subsequent clinical trials.
- Trial name
- NCT05620017
- Testing
- BAT8008 for Injection
- Where
- 2 sites in China
- Volunteers
- 182 people
- Sponsor
- Bio-Thera Solutions
Advanced Solid Tumors
Safety and Efficacy of LCL161 in Patients With Solid Tumors
The study will evaluate the safety of increasing doses of oral LCL161 in patients with solid tumors. It is primarily designed to evaluate the side effects and find the maximum tolerated dose of LCL161.
- Trial name
- NCT01098838
- Testing
- LCL161
- Where
- 3 sites in United States
- Volunteers
- 71 people
- Sponsor
- Novartis Pharmaceuticals
Advanced Solid Malignancies
Phase I Study of GW572016 With Topotecan to Treat Advanced Solid Malignancies
Participants will take GW572016 by mouth daily each cycle (cycles 28 days in length) and will be given Topotecan intravenously on Days 1, 8 and 15.
- Trial name
- NCT00295243
- Testing
- Topotecan
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Mayo Clinic
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.